Actively Recruiting

Phase Not Applicable
Age: 55Years - 100Years
All Genders
Healthy Volunteers
NCT06150261

Effects of an Omega-3 Fatty Acid-based Supplement on Healthy Ageing

Led by Helse Stavanger HF · Updated on 2025-01-14

100

Participants Needed

1

Research Sites

107 weeks

Total Duration

On this page

Sponsors

H

Helse Stavanger HF

Lead Sponsor

E

Evonik Industries AG

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this randomised, double-blind placebo controlled trial is to explore tolerability and the effects of a new omega-3 fatty acid-based supplement on biological and clinical aspects relevant for healthy ageing. Participants will be asked to take a supplement or a placebo for 6 months, and to attend the clinic a total of 3 times and to perform or submit the following: * Physical examination * Muscle function tests * Cognitive testing * Questionnaire completion * Biological samples, including blood, saliva and faeces. Researchers will compare the results from the group taking the supplement to the results of the group taking a placebo to see if the supplement has an effect on biological and clinical aspects associated with healthy ageing.

CONDITIONS

Official Title

Effects of an Omega-3 Fatty Acid-based Supplement on Healthy Ageing

Who Can Participate

Age: 55Years - 100Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 55 or more
  • BMI between 25 and 30
  • Waist-to-hip ratio of at least 0.90 for males or 0.85 for females
  • Omega-3 index less than 6
Not Eligible

You will not qualify if you...

  • Dementia
  • Current clinically significant depression (major depression or GDS 15 score greater than 7)
  • Ischemic or hemorrhagic stroke
  • Acute myocardial infarction
  • Any clinically significant atherosclerotic cardiovascular disease
  • Unstable angina pectoris
  • Heart failure requiring treatment
  • Type 1 or type 2 diabetes mellitus
  • Clinically relevant kidney diseases requiring dialysis, including chronic kidney disease
  • Liver cirrhosis or active hepatitis B or C
  • Any cancer except benign tumors
  • Clinically relevant inflammatory or autoimmune disorders with hospitalization history
  • Systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, Parkinson's disease, or multiple sclerosis
  • High hsCRP levels above 3.0 mg/L
  • LDL cholesterol above 160 mg/dL
  • Hemoglobin A1C below 6.5% to exclude diabetes
  • Fasting triglycerides above 200 mg/dL
  • Omega-3 index above 6%
  • Use of fish oil or omega-3 supplements in the last 6 months
  • Fish allergy
  • Antibiotic use in the last 24 weeks

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Stavanger Universitetssjukehus

Stavanger, Norway

Actively Recruiting

Loading map...

Research Team

D

Dag Aarsland, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here